In tumour without BRAFV600E mutation, extensive screening is valuable to identify an alternative druggable genetic alteration of the MAPK pathway (e.g., gene fusion involving BRAF, RAF1, ALK, ROS1). This evidence concerns the gene BRAF and neoplasm.